Linked Life Data

15936510

Source:http://linkedlifedata.com/resource/pubmed/id/15936510

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-2
pubmed:dateCreated
2005-6-6
pubmed:abstractText
NGP1-01, a member of the pentacycloundecylamine cage compound family, was recently shown to exhibit both NMDA receptor channel blocking and L-type calcium channel antagonism activity. In the present study, focal ischemia was induced in mice by permanent middle cerebral artery occlusion (MCAO) to test for potential neuroprotective properties of the compound. In female CD-1 mice injected 30 min before MCAO, NGP1-01 (20 mg/kg) reduced infarct area by 42.6% (P < 0.05) compared to vehicle-treated controls as visualized by 2,3,5-triphenyltetrazolium chloride (TTC) staining. Concomitantly, NGP1-01 reduced brain swelling by 78.3% (P < 0.001), compared to vehicle (DMSO) treated controls. These data identify NGP1-01 and related compounds as potential lead structures to develop neuroprotective compounds based on a dual mechanism of action.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0304-3940
pubmed:author
pubmed:issnType
Print
pubmed:volume
383
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
49-53
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:articleTitle
NGP1-01, a lipophilic polycyclic cage amine, is neuroprotective in focal ischemia.
pubmed:affiliation
Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University HSC, Amarillo, 79106-1712, USA.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't